Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

United States and EU5 Celiac Disease Market Insights, Epidemiology and Market Forecasts Report 2016-2023 - Research and Markets

Research and Markets
Posted on: 17 Oct 16

Research and Markets has announced the addition of the "Celiac Disease (CD)-Market Insights, Epidemiology and Market Forecast - 2023" drug pipelines to their offering.

Estimates suggest that the global market size is expected to grow at a CAGR of 19% from 2013-2023.

Celiac Disease (CD)- Market Insights, Epidemiology and Market Forecast-2023 report provides an overview of the disease and global market size of the Celiac Disease for the 6MM (United States and EU5 countries (France, Germany, Italy, Spain and UK)). It also includes global historical and forecasted epidemiological data for the diagnosed prevalent cases of Celiac Disease from 2013-2023.

Celiac disease is a genetic autoimmune disease where the indigestion of gluten leads to damage in the small intestine. The number of ways celiac disease can affect patients, combined with a lack of training in medical schools and primary care residency programs, contributes to the poor diagnosis rate. Currently it is estimated that 80% of the celiac disease population remains undiagnosed. Prevalence in Western Europe and in the United States ranges between 1 in 250 and 1 in 133. It is higher in relatives of people with celiac disease. Women are affected more commonly than men, but there is no age predilection.

Forecasts predict that the total prevalent cases of Celiac Disease is expected to accentuate up to 4.69 Million by 2023 at a Compound Annual Growth Rate (CAGR) of 0.46% from 2013-2023 while the diagnosed prevalent population of Celiac Disease in the 6MM shall grow at a CAGR of 0.15% for the forecast period (2013-2023).

There is no targeted therapy approved for celiac disease. The current standard of care treatment involves a gluten free diet (GFD). Steroids and immunosuppressants are used to reduce symptoms in severe cases. Owing to the expected launch of Larazotide Acetate (Innovate Pharmaceuticals) in 2021 followed by the launch of Latiglutenase (ImmunogenX/Abbvie) in 2023, shall lead to a hike in the otherwise stable, worldwide market size of celiac disease.

Key Topics Covered:

  1. Report Introduction
  2. Celiac Disease Market Size Overview at a Glance
  3. Worldwide Market Size of Celiac Disease in 2013
  4. Worldwide Market Size of Celiac Disease in 2023
  5. Celiac Disease Overview
  6. Celiac Disease Types
  7. Non-Responsive or Refractory CD
  8. Etiology
  9. Symptoms
  10. Diagnosis
  11. Disease Management
  12. Disease Treatment
  13. Treatment of Celiac Disease
  14. Treatment of Non-Responsive or Refractory Celiac Disease (RCD)
  15. Current Unmet Medical Needs
  16. Epidemiology Parameters
  17. Iceberg Model
  18. Genetic Predisposition
  19. Epidemiology &Patient Population
  20. United States
  21. EU5 Countries

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 17/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.